11/15/18 Ruxolitinib Moves On Without Me

I started the BATCC clinical trial on ruxolitinib on June 17, 2016. It was a two year trial designed test the effectiveness of ruxolitinib on alleviating the symptoms of CLL (fatigue, bone pain, joint pain, and others) by targeting cells that carried the JAK-7 enzyme, which produces inflammation. Inflammation is the source of many diseases…

5/12/18 Summer’s Here

No. It’s not really summer, yet, but today sure seemed like it. Summers seem harsher here than they used to be. Maybe my tolerance is faltering. Lots of things at my age are faltering. I am glad to be still be here. We have been working long hours in Olive Branch, Mississippi, in the throes…

4/15/18 Two More Years

I have been on the Ruxolitinib trial for two years now. It has been good so far. The trial was designed to address the symptoms of CLL and prove, disprove, or measure its efficacy in individual patients. The requirements of the trial were that each person enrolled must not be treatment naive, meaning that they…

10/5/17 Troubles….Everywhere…Well, Nearly Everywhere

My trip to Houston for a checkup was enlightening. I saw much that the otherwise unobserving eye might have missed. I don’t miss much, though; after all, my name is Sharp. I had been to see Hemosapien on 9/27/17. I had not seen him in a while since I have been on this clinical trial…

12/12/16 A Complicated World

12/9/16 It’s a complicated world out there. Politics, economics, terrorism, globalism, hegemony, wars, pestilence, earthquakes, storms …so many things just waiting for a chance to manifest themselves to interfere with our lives. So many of those things are beyond our control, leaving used tossed on stormy seas, cast adrift in shallow draft lifeboats, bobbing around…

11/21/14 I Know That This Is the CLL Blog

I have CLL. I write about CLL. But I have been given an opportunity to write about other things because my CLL is not on high on the front burner. I am no longer in MRD status, and back on watch and wait, all while seeing the encroaching signs of accelerating status. I will return…